Long-Term Remission With Allo-HSCT for t(1;8)(q25;p11) Translocation: A Rare Case Report and Literature Review.

Background: The 8p11 myeloproliferative syndrome (EMS), a rare disorder characterized by translocations and interchanges at chromosome 8p11, is usually refractory to chemotherapy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only promising treatment for long-term remission. Among 14 translocation partners associated with EMS, t(1;8)(q25;p11) are very uncommon, with only four cases previously reported in peer-reviewed journals in English.

Case presentation: Here we report a 43-year-old man who presented with atypical peripheral T-cell lymphomas. Translocations between chromosomes 1q25 and 8p11 were detected during a bone marrow karyotype examination of 20 metaphases, and fluorescence in situ hybridization (FISH) revealed a positive rearrangement for the FGFR1 locus, confirming the diagnosis of EMS with t(1;8)(q25;p11). Despite rapid disease progression, he maintained remission for 27 months after admission due to aggressive chemotherapy combined with early allogeneic peripheral blood stem cell transplantation. We also conducted a literature review for 12 EMS patients treated with allo-HSCT who had rare karyotypes to better understand their clinicopathologic features and disease management.

Conclusion: we report the first case of EMS with t(1;8)(q25;p11) to have a favorable outcome after allo-HSCT. The encouraging results support the use of aggressive chemotherapy in conjunction with early allo-HSCT for EMS patients with t(1;8)(q25;p11).